



**FOR IMMEDIATE RELEASE**

**Contact:**  
Paul Byerley  
Chief Executive Officer  
+1 320.259.4321  
[pbyerley@artossinc.com](mailto:pbyerley@artossinc.com)

## Artoss, Inc. Recruits 100 Patients in Key Clinical Study on NanoBone® Bone Graft in Spinal Fusion

### **Early ASTRO Study Experience Supports NanoBone Standalone Performance**

St. Cloud, MN, May 26, 2021 / -- Artoss, Inc. (St. Cloud, MN), a medical device company that is pioneering the use of advanced bone graft substitutes to treat multiple orthopaedic indications, announced the enrollment of the first 100 patients in the Artoss Prospective Spine Registry Outcomes (ASTRO) Study, exceeding its initial recruitment objectives.

ASTRO was designed as a prospective observational study of NanoBone Bone Graft (both SBX Putty and QD) performance in spinal fusion and determine relevant patient outcomes, including radiographic measures such as fusion outcome, instrumentation integrity, and clinical outcomes (symptom and function improvement) based on investigator and patient-based outcome assessments. The primary objective of ASTRO is to document and analyze the use of NanoBone SBX Putty and QD in spinal fusion surgery (as a stand-alone bone graft, or in combination with local bone only, with no other products used) and determine both radiographic success and clinical outcomes.

Steve Czop, R.Ph., Director of Regulatory and Clinical Affairs at Artoss, Inc., the exclusive North American distributor for NanoBone in orthopaedic surgery, stated, "As we reach this major milestone, we'd like to thank our spine surgeon investigators and research coordinators who have joined us in ASTRO. We appreciate their hard work in this investigation of NanoBone as a standalone product enhancing spinal fusion. The response in ASTRO as well as commercially in the U.S. indicates that NanoBone represents the best standalone synthetic bone graft on the market."

"I am pleased with my use of NanoBone in the ASTRO Study to-date," said Dr. Lyle Young of Sonoran Spine in Scottsdale, Arizona. "I have used multiple bone graft substitutes and rarely seen a rapid healing response in standalone products. NanoBone has great handling and it's ready out of the box, which allows me greater focus on my surgical approach. My early follow-up with NanoBone supports the rapid osteogenesis expected from NanoBone Bone Graft Substitute."

NanoBone has consistent outcomes in bone grafting in multiple orthopaedic indications. NanoBone achieves these outcomes with no preparation required, excellent handling for

surgeons, and creation of an osteogenic matrix within 14 days. There is growing acceptance by surgeons that not all bone graft substitutes are the same. The dramatic growth in NanoBone procedures supports this and secures its market position as a leader in the bone repair space.

###

#### **About NanoBone**

NanoBone was first cleared by the Food and Drug Administration (FDA) in 2015 after having been successfully used in Europe for ten years. Clinical publications have identified bone graft substitutes as an increasingly important component of many orthopaedic procedures. Consistent healing in orthopaedic procedures is a significant unmet clinical need and one where NanoBone may provide an effective option.

NanoBone is a commercially available product in the U.S. intended to fill bony voids or gaps of the skeletal system (i.e., extremities, posterolateral spine and pelvis). These osseous defects are surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. NanoBone<sup>®</sup> SBX Putty resorbs and is replaced with bone during the healing process. Artoss and NanoBone are trademarks of Artoss GmbH.

###

#### **About Artoss, Inc.**

Artoss, Inc. (St. Cloud, MN) is a medical device company that is a leading distributor of bioidentical bone graft substitutes to treat multiple orthopaedic indications and is dedicated to the development of tools and products for effectively treating a variety of orthopaedic conditions requiring surgical intervention. The company markets, NanoBone Bone Graft, which gives clinical outcomes comparable to autograft with less postoperative pain and complications. Artoss, Inc. has an experienced management team with extensive experience in orthopaedic medical devices.